Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
Kennedy Institute of Ethics Journal|November 10, 2006
Depression, SSRIs, and the supposed obligation to suffer mentallyJ Mark OlsenEpigenetics|September 6, 2012
FTO, RNA epigenetics and epilepsyJoie Rowles, Morgan Wong, Ryan Powers, et al.Journal of Experimental & Clinical Cancer Research : CR|August 20, 2020
Aspartate β-hydroxylase as a target for cancer therapyMadiha Kanwal, Michal Smahel, Mark Olsen, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 24, 2025
Unveiling the transformative power of near-infrared spectroscopy in biomedical and pharmaceutical analysis: Trends, advancements, and applicationsJiri Kos, Denis Pavelek, Massoud Kaykhaii, et al.Journal of Cancer|May 31, 2024
Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylaseMadiha Kanwal, Ingrid Polakova, Mark Olsen, et al.Antimicrobial Agents and Chemotherapy|January 17, 2025
Protamine protects against vancomycin-induced kidney injuryJustin Shiau, Patti Engel, Mark Olsen, et al.Journal of Feline Medicine and Surgery|October 22, 2021
Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitroSarah E Cook, Helena Vogel, Diego Castillo, et al.RNA Biology|February 7, 2024
Epitranscriptomic regulation in fasting hearts: implications for cardiac healthDaniel Benak, Kristyna Holzerova, Jaroslav Hrdlicka, et al.Plos One|July 9, 2016
Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic ChallengeBalraj Singh, Hannah E Kinne, Ryan D Milligan, et al.Cancer Chemotherapy and Pharmacology|September 21, 2007
Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trialH Ian Robins, Anne O'Neill, Mark Gilbert, et al.Pageof 3